Company Overview and News

10
Biotech Analysis Central Pharma News: Zogenix's Late-Stage Win, Zynerba's Bounce Back, Abbvie's Expanded Venetoclax Use

8h seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.
ABBV ZYNE ZGNX ABBV GWP

25
Your Daily Pharma Scoop: Zogenix Zooms, Zynerba's Changing Fortunes, AbbVie Proceeds

2018-07-15 seekingalpha
Discussion: Zogenix (ZGNX) announced positive result of a second Phase 3 clinical trial of its ZX008 (low-dose fenfluramine hydrochloride) in Dravet syndrome. The disease is a rare and severe form of epilepsy in children and young adults. Patients in the group under trial experienced a significant betterment, of 54.7% (compared to placebo) decrease in mean monthly convulsive seizures. Both the key secondary endpoints were also met by the trial results.
SGEN AST.WS XLRN AST XNCR CELG GSK ABBV ZYNE ZGNX GSK ABBV

0
Zynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome

2018-07-12 globenewswire
- Significant Improvements in Behavioral Symptoms Observed in Patients and Sustained through 38 Weeks of Treatment with ZYN002 - - Presentation Today at the 16th NFXF International Fragile X Conference -
ZYNE

56
Your Daily Pharma Scoop: IsoRay Doubles, OncoCyte Zooms, Celgene Sluggish

2018-07-11 seekingalpha
Note: ISR has a market cap of less than $100mn and trades below $1. These stocks are inherently risky, and we do not invest in such stocks. However, on Monday, on this news, the stock went above $1, which is when we covered it.
BLU CYTX TEVA ISR TEVVF ZYNE NGS AVXL SNGX VRX INSP ACRS CYTXW BLUSF CELG CTYX OCX GLPG KMPH VRX GLPG CTIC CTI EGRX XLRN TEVJF PTCT

0
Zynerba Misses Mark For THC Patch Trial, But Its Value Remains With Other Assets

2018-07-09 seekingalpha
Zynerba Pharmaceuticals didn't achieve the study goals for ZYN001 which means it has to cut the program from its pipeline.
ZYNE

1
Zynerba: Does The Investment Case Still Hold?

2018-07-09 seekingalpha
Small cap Zynerba Pharmaceuticals had an eventful week as it discontinued development of one of the compounds in its pipeline.
ZYNE THC

85
Major Biopharma Catalysts on July’s FDA Calendar

2018-07-07 247wallst
Biotech and pharmaceutical companies are generally involved in the lengthy process of getting their drug candidates to market through clinical trials. The amount of risk involved ranges from fair to great, should a study come back negative or a candidate not be approved. Conversely, if a drug is approved or passes a clinical trial, there can be massive upside.
CBIO TBPH NBIX GSK ZYNE ABBV GSK ABBV DRRX PGNX

0
GW And Epidiolex: Are Sales Already Baked In?

2018-07-05 seekingalpha
GW has seen incredible price appreciation over the past 5 years due to good news surrounding their lead cannabinoid product, Epidiolex.
NMUS ZYNE GWP

0
Zynerba Scraps Development of THC Prodrug ZYN001 after Failed Trial

2018-07-05 genengnews
Cannabinoid-based drug developer Zynerba Pharmaceuticals will halt development of its THC prodrug candidate ZYN001 following its failure in a clinical trial, and instead refocus its development effort and investment on CBD permeation-enhanced gel ZYN002. [©Fotolia V]
ZYNE

0
GW & Epidiolex: Are Sales Already Baked In?

2018-07-05 seekingalpha
GW has seen incredible price appreciation over the past 5 years due to good news surrounding their lead cannabinoid product, Epidiolex.
NMUS ZYNE GWP

0
Why Zynerba Shares Are Getting Crushed

2018-07-05 247wallst
Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) shares were crushed early on Thursday after the company reported topline results from an early stage clinical study. Specifically, the firm announced results from a Phase 1 clinical program studying ZYN001, the company’s patent-protected, pro-drug of tetrahydrocannabinol (THC) delivered via a transdermal patch, in healthy volunteers.
ZYNE

1
Zynerba shares slide 17% after trial of cannabis-based skin patch fails to meet goals - MarketWatch

2018-07-05 marketwatch
Shares of Zynerba Pharmaceuticals Inc. ZYNE, -0.93% slid about 17% in premarket trade Thursday, after the company said an early-stage trial of a cannabinoid skin patch failed to meet its main goals. The company, which is developing cannabis-based therapies for rare neruospsychiatric disorders, said the trial of ZYN001, a patent-protected, pro-drug of tetrahydrocannabinol (THC) delivered via a transdermal patch, in healthy volunteers, did not achieve its goal of target blood levels of 5 to 14 ng/ml THC.
ZYNE

1
Zynerba Pharmaceuticals Announces Top Line Results from ZYN001 THC-Prodrug Patch Phase 1 Study

2018-07-05 globenewswire
DEVON, Pa., July 05, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, announced top line results from a Phase 1 clinical program studying ZYN001, the Company’s patent-protected, pro-drug of tetrahydrocannabinol (THC) delivered via a transdermal patch, in healthy volunteers.
ZYNE

ZYNE: Zynerba Pharmaceuticals Analysis and Research Report

2018-04-08 - Asif

Company Overview Zynerba Pharmaceuticals is a clinical stage specialty pharmaceutical company dedicated to the development and commercialization of innovative transdermal pharmaceutically-produced cannabinoid treatments for rare (meeting the U.S. Food and Drug Administration’s, or FDA’s, designation of an orphan disease, affecting fewer than 200,000 people in the United States) and near-rare (affecting fewer than one million people in the United States) neurological and psychiatric, or neuropsychiatric, disorders in patients with high unmet medical needs. Zynerba Pharmaceuticals is currently evaluating two patent protected product candidates, ZYN002 and ZYN001, in four neuropsychiatric indications. In 2017, the company completed three Phase 2 clinical trials for ZYN002 and two of those studies have open-label extensions that are ongoing. In 2018 the company plan to initiate additional clinical trials evaluating ZYN002 for the treatment of behavioral symptoms of Fragile X syndr...

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

6h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

CUSIP: 98986X109